42
13. Coates, AS; Keshaviah, A; Thürlimann, B; et al. Five years of letrozole compared with
tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-
responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492.
14. Goss, PE; Ingle, JN; Martino, S; et al. A randomized trial of letrozole in postmenopausal
women after five years of tamoxifen therapy for early-stage breast cancer. N Eng J Med
2003; 349(19): 1-10.
15. Goss, PE; Ingle, JN; Martino, S; et al. Randomized trial of letrozol following tamoxifen as
extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC
CTG MA.17. J Natl Cancer Inst 2005; 97(17):1262-1271.
16. Coombes, RC; Hall, E; Gibson, LJ; et al. A randomized trial of exemestane after two to
three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N
Eng J Med 2004; 350:1081-1092.
17. Coombes, RC; Kilburn, LS; Snowdon, CF; et al. Survival and safety of exemestane versus
tamoxifen after 2-3 years’ tamoxifen treatment (Intergroup Exemestane Study): a
randomized controlled trial. Lancet 2007; 369: 559-570.
18. Winer, EP; Hudis, C; Burstein, HJ; et al. American Society of Clinical Oncology
Technology Assesment on the use of aromatase inhibitors as adjuvant treatment for
postmenopausal women with hormone-receptor-positive breast cancer: status report 2004.
J Clin Oncol 2005; 23 (3): 1-11.
19. Hamilton, A; Hortobagyi, G. Chemotherapy: what progress in the last 5 years? J Clin
Oncol 2005; 23:1760-1775.
20. Citron, ML; Berry, DA; Cirrincione, C; et al. Randomized trial of dose-dense versus
conventionally scheduled and sequential versus concurrent combination chemotherapy as
postoperative adjuvant treatment of node-positive primary breast cancer: first report of
Intergroup Trial C9741 / Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;
21: 1431-1439.
21. Henderson, IC; Berry, DA; Demetri, GD; et al. Improved outcomes from adding
sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant
chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol
2003; 21(6): 1-9.
22. Mamounas, EP; Bryant, J; Lembersky, B; et al. Paclitaxel after doxorubicin plus
cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from
NSABP B-28. J Clin Oncol 2005; 23:3686-3696.
23. Martin, M; Pienkowski, T; Mackey, J; et al. Adjuvant Docetaxel for node-positive breast
cancer. N Eng J Med 2005; 352: 2302-2313.
24. Roche, H; Fumoleau, P; Spielmann, M; et al. Sequential adjuvant epirubicin-based and
docetaxel chemotherapy for node positive-breast cancer patients: the FNCLCC PACS 01
trial. J Clin Oncol 2006; 24:5664-5671.
25. Winer, EP; Piccart-Gebhart, MJ; Rugo, HS; Sledge Jr, GH. Management of HER2-
positive breast cancer. In: ASCO Educational Book 2006.